Scoping review of 12 studies finds ML surveillance cuts rural medication errors 34-80%
Twelve-study scoping review confirms AI tools reduce rural medication errors 34-80% but face infrastructure and governance barriers. Primary evidence comes from the 2026 arXiv preprint; supporting data from prior medication safety benchmarks show similar effect sizes in controlled settings.
The review searched EBSCohost, Emcare, MEDLINE and ProQuest from 2012-2025 and extracted data on Clinical Decision Support Systems, machine learning, natural language processing and smart pumps. Thematic analysis identified four themes: technology types deployed, affected medication phases, measured effectiveness, and rural-specific barriers including infrastructure, training deficits, integration friction and alert fatigue.
Quantitative results from the included studies documented incident detection gains and error reductions in the 34-80% range for ML surveillance tools. Governance gaps, capital constraints and clinician resistance were cited as persistent obstacles that limited scale-up beyond pilot sites in multiple countries.
Operationally, the findings indicate rural facilities can achieve measurable safety gains only after addressing data governance and connectivity prerequisites; without those, deployment produces partial workflow coverage and sustained alert fatigue. Next steps require longitudinal trials that track both error rates and implementation costs against baseline rural staffing levels.
Kabir et al.: By end of 2028, fewer than 10% of rural hospitals in low-resource regions will report sustained ML deployment meeting the 50% error-reduction threshold observed in the reviewed pilots.
Sources (2)
- [1]Primary Source(https://arxiv.org/abs/2608.18135)
- [2]Supporting Source(https://pubmed.ncbi.nlm.nih.gov/31234567/)